Japan’s Ministry of Health, Labor and Welfare (MHLW) on March 5 unveiled the revised NHI prices for drugs subject to…
HOME > BUSINESS
BUSINESS
- Daiichi Sankyo Grabs Europe Rights to 1st-in-Class Cholesterol Drug
January 8, 2019
- Fujifilm to Make 10 Billion Yen Capital Investment in Bio CDMO Business
January 8, 2019
- Kaken Licenses Systemic Sclerosis Treatment from Corbus in Japan
January 8, 2019
- J-TEC’s Cell Sheet JACE Approved for Epidermolysis Bullosa
January 8, 2019
- Sumitomo Dainippon Corrects Announcement on US Latuda Settlement
January 7, 2019
- JCR Completes Patient Enrolment in Japan PIII Study for Hunter Syndrome Treatment
January 7, 2019
- Nipro to Strive for Stable Supply of Stemirac, 1st Stem Cell Therapy for Spinal Cord Injury
January 7, 2019
- Can Daiichi Sankyo Take Big Leap in Oncology with 3 FDA Nods in FY2019?
January 4, 2019
- Japan Gives Conditional OK to 1st Stem Cell Therapy for Spinal Cord Injury
December 28, 2018
- Reata Developing Sakigake Designated DKD Drug for Alport Syndrome in Japan
December 28, 2018
- Kyorin, Hebrew University Link Arms in Respiratory Drug Development
December 28, 2018
- Ono Files Heart Failure Drug Ivabradine in Japan
December 28, 2018
- Chugai Obtains Approval of First Dual-Function Gene Panel Test
December 28, 2018
- Biogen Japan Set to “Make Impossible Possible” in Next 5 Years, Double Neuroscience Pipeline
December 27, 2018
- Crestor Generics of Nichi-Iko, Towa Now Have Full Indications
December 27, 2018
- Xofluza Most Heavily Promoted Drug for GP in October: Anterio
December 27, 2018
- First Cancer Gene Panel Test Approved in Japan: Sysmex
December 27, 2018
- Japan Vaccine to Transfer Business to Daiichi Sankyo, GSK in April
December 27, 2018
- Fuji Pharma Shooting for 2.6-Fold Sales Increase by 2030: President
December 26, 2018
- Sumitomo Dainippon to Merge Authorized Generic Units
December 26, 2018
ページ
Japan’s pharmaceutical policy appears to be entering a new phase. The government’s newly approved honebuto policy and growth strategy both…
A few weeks ago, I had coffee with a very talented executive. Let’s call him Kenji. He has a great job, a big salary, and a solid team. But he was unhappy. He felt bored and wanted a new challenge.…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…